BusinessMinerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22By Nasdaq OMXMar 15, 2018, 12:30 PM UTC
BusinessMinerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business UpdatesBy Nasdaq OMXMar 12, 2018, 11:30 AM UTC
BusinessMinerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in SchizophreniaBy Nasdaq OMXDec 19, 2017, 1:01 PM UTC
BusinessMinerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in SchizophreniaBy Nasdaq OMXFeb 21, 2017, 1:30 PM UTC
